Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Meth Bill Draft Offers Quicker Review of Pseudoephedrine Replacements

This article was originally published in The Tan Sheet

Executive Summary

Cough/cold medications reformulated to exclude pseudoephedrine would receive expedited review by FDA under a provision included in a recent draft of the Combat Meth Act

You may also be interested in...

Phenylephrine Products Proliferate Due To Pseudoephedrine Restrictions

The growing trend of limiting pseudoephedrine accessibility in stores is driving an expanding market for nasal decongestant alternatives containing phenylephrine

Retailers Put Pseudoephedrine Behind Counters, Lend Weight To Talent Bill

A wave of decisions from leading OTC drug retailers to place pseudoephedrine solids behind the counter could provide momentum for a federal pseudoephedrine BTC bill

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts